Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPR206 in Healthy Volunteers
NCT03792308Phase 1Completed
- Sponsor
- Spero Therapeutics
- Start
- Dec 2018
- Primary completion
- Dec 2019
- Modality
- Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Gram-negative bacterial infection comparing SPR206 with Placebo (2 arms). Primary endpoint: Treatment Emergent Adverse Events up to 28 days. Started Dec 2018; status: completed.
02
Drugs
SPR206
03
Conditions
Gram-negative bacterial infection
Beyond the preview
Go deeper on NCT03792308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03792308.